European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelin...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology Vol. 23; no. 3; pp. 302 - 312
Main Authors: Frisoni, Giovanni B, Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Borroni, Barbara, Cappa, Stefano F, Frederiksen, Kristian S, Froelich, Lutz, Garibotto, Valentina, Haliassos, Alexander, Jessen, Frank, Kamondi, Anita, Kessels, Roy PC, Morbelli, Silvia D, O'Brien, John T, Otto, Markus, Perret-Liaudet, Armand, Pizzini, Francesca B, Vandenbulcke, Mathieu, Vanninen, Ritva, Verhey, Frans, Vernooij, Meike W, Yousry, Tarek, Boada Rovira, Mercè, Dubois, Bruno, Georges, Jean, Hansson, Oskar, Ritchie, Craig W, Scheltens, Philip, van der Flier, Wiesje M, Nobili, Flavio
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.03.2024
Elsevier Limited
Subjects:
Agreements
Alzheimer Disease - diagnosis
Alzheimer's disease
Aphasia
Atrophy
Basic Medicine
Biomarkers
Cognition
Cognitive ability
Consensus
Dementia
Diagnosis
Disease
Epilepsy
Europe
Humans
Literature reviews
Medical and Health Sciences
Medical diagnosis
Medical imaging
Medicin och hälsovetenskap
Medicinska och farmaceutiska grundvetenskaper
Memory
Neurodegeneration
Neurodegenerative diseases
Neuroimaging
Neurological disorders
Neuropsychology
Neurosciences
Neurovetenskaper
Patients
Scintigraphy
Societies, Scientific
Europe
ISSN:1474-4422, 1474-4465, 1474-4465
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-4422
1474-4465
1474-4465
DOI:10.1016/S1474-4422(23)00447-7